Evotec Slips to Loss in Q3, Revenues Rise; Lifts FY22 Revenue View, Backs Adj. EBITDA forecasts

(RTTNews) – Evotec AG (EVTCY.PK), a German drug discovery and development company, announced on Thursday that its net loss attributable to shareholders in the third quarter was 27.94 million euros, compared to a profit of 60.02 million euros last year.

The loss per share amounted to 0.16 euros, against a profit of 0.37 euros a year ago.

Net operating loss for the quarter amounted to 3.77 million euros, compared to a profit of 1.54 million euros a year ago.

The turnover of the group increased to 172.20 million euros against 138.22 million euros the previous year.

For the 2022 financial year, the company now expects Group revenues to be in the range of €715 million to €735 million, compared to €700 million to €720 million previously forecast. Last year’s revenue was 618 million euros.

In addition, the Group’s adjusted EBITDA should still be between 105 and 120 million euros, compared to 107 million euros last year.

The medium-term objectives are aimed at revenue growth of more than 1 billion euros and an adjusted EBITDA of at least 300 million euros.

For more earnings news, earnings calendar and stock earnings, visit rttnews.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Comments are closed.